Short answer
Moderna (MRNA) filed an 8-K current report with the SEC on March 5, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). Moderna settles all global LNP patent litigation with Arbutus/Genevant for a mandatory $950M lump sum due by July 8, 2026.
Moderna 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Moderna settles all global LNP patent litigation with Arbutus/Genevant for a mandatory $950M lump sum due by July 8, 2026
- Additional $1.3B contingent payment triggered if Federal Circuit rejects Moderna's §1498 defense; worst-case total exposure = $2.25B
- If §1498 bars only some infringing doses, contingent payment prorated below $1.3B; if Moderna wins fully, no additional payment owed
- Settlement grants Moderna royalty-free, irrevocable, worldwide LNP license covering Spikevax, mNEXSPIKE, mRESVIA, and full future infectious disease pipeline: eliminates ongoing royalty drag
- Litigation certainty for entire vaccine portfolio is strategically significant, removing a key overhang that threatened commercial and pipeline viability
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Moderna 8-K filings
Get the next MRNA 8-K as it lands
Follow MRNA for push alerts, or ask the research agent what this filing means.